FLEX Company

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Bluebird Will Use Inhibrx’s

Investors can't get enough of companies that are developing drugs to treat non-alcoholic steatohepatitis (NASH), more than doubling the value of two small biopharmaceutical firms based on recent mid-s

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer